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Hemophilia (HL): 
definition 
HL is a group of a sex-linked hereditary genetic disorders that occurs 
almost exclusively in males and impairs the body's ability to control blood 
clotting, which is used to stop bleeding when a blood vessel is broken 
even after minor injuries 
Types:  
• HL A (clotting factor VIII deficiency)  is a recessive X-linked most 
common form of the disorder which  occurs in 1 in 5,000–10,000 male 
births 
• HL B (factor IX deficiency)  is a recessive X-linked form of the disorder 
which occurs in 1 in 20,000–34,000 male births  
• HL C  or plasma thromboplastin antecedent (PTA) deficiency or 
Rosenthal syndrome (factor XI deficiency) is an autosomal (i.e. not X-
linked) genetic disorder which occurs in both sexes  
http://www.merriam-webster.com/dictionary/hemophilia https://en.wikipedia.org/wiki/Haemophilia  
http://emedicine.medscape.com/article/955690-overview    
Hemophilia (HL): 
epidemiology   
Global distribution of total reported cases of bleeding disorders (a) and HL A (c) in five 
countries reporting the highest number of patients (b) and (d) show s that nearly 5 and 9% 
of global patients with bleeding disorders and HL A are from India 
http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2014;volume=140;issue=1;spage=19;epage=31;aulast=Kar  
Hemophilia (HL): 
epidemiology   
Distribution by age for patients with HL A&B: median age for patients 
diagnosed with mild HL was 3 years for HA and 5 for HB  
http://www.revhematologia.sld.cu/index.php/hih/article/view/145/118  
Hemophilia (HL): 
risk factors and etiology 
• Risk factors for HL include family history of bleeding and almost  always being male 
• HL is caused by an inherited X-linked recessive trait, with the defective gene located on 
the X chromosome 
• Males have only one X chromosome, and if the factor VIII gene or if the factor IX gene 
is missing on a boy's X chromosome, he will have HL A or HL B 
• If a woman has a defective factor VIII gene or a defective factor  IX gene, she is 
considered a carrier: boys born to such women have a 50% chance of having 
hemophilia A or hemophilia B, and their daughters have a 50% chance of being a 
carrier 
• HL C with deficiency of factor XI was described first in 2 sisters and a maternal uncle of 
an American Jewish family after bled from dental extractions;  unlike the bleeding 
tendency in HL A or HL B, which is clearly related to the factor level, the bleeding risk in 
HL C is not always influenced by the severity of the deficiency, especially in individuals 
with partial deficiency  
• All female children of men with HL carry the defective gene  
 
http://emedicine.medscape.com/article/955690-overview   
https://www.nlm.nih.gov/medlineplus/ency/article/000538.htm  
Hemophilia (HL): 
risk factors and etiology 
http://www.moh.gov.sa/en/HealthAwareness/EducationalContent/Diseases/Hematology/Pages/006.aspx  
Hemophilia (HL): 
mechanisms 1 
Normal blood clotting is a complex process requiring as many as 20 blood proteins, or clotting 
factors. The deficiency or absence of one of these factors may disrupt the clotting process 
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
Hemophilia (HL): 
mechanisms 2 
Diagram showing how in hemophilia patients, blood cannot clot properly 
because of poor platelet plug 
http://www.koate-dviusa.com/about-hemophilia-a-pages-13.php  
Hemophilia (HL): 
severity classification   
• HL is classified as mild, moderate, or severe depending on the amount of the clotting 
factor present in a person’s blood 
• The normal range of FVIII and FIX is between 50% and 150% 
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
Severity 
Blood clotting 
factor level 
Normal 50%-150% 
Mild 
hemophilia 
6%-49% 
Moderate 
hemophilia 
1%-5% 
Severe 
hemophilia 
<1% 
 
•In mild HL , bleeding problems occur after injury, 
trauma, or surgery; the condition may have very few 
symptoms otherwise - 25% of the HL population 
•In moderate HL  bleeding episodes tend to occur after 
minor injuries, though in some cases spontaneous 
bleeding episodes may occur - 15% of the HL 
population 
•In addition to bleeding after injury, trauma, or 
surgery, severe hemophilia characterized by 
spontaneous bleeding into joints and muscles - 60% of 
the HL population 
 
Hemophilia (HL):  
clinical presentation 1 
• All symptom of HL are related to uncontrolled or unexpected bleeding, either 
externally (e.g. skin cut, nosebleed) or internally (e.g. knee, muscle, brain) 
• The extent of bleeding depends on the amount of functional clotting factors 
present in the body; when the amount of clotting factor is low, bleeding symptoms 
become more severe 
• Internal bleeding into the joints, muscle and brain is serious and requires 
immediate medical attention 
• The following bleeding symptoms are associated with HL: 
• Excessive bleeding following minor injuries (e.g. skin cut) 
• Large skin bruises from bleeding within the skin 
• Uncontrolled bleeding after receiving a shot or pulling a tooth 
• Frequent nosebleeds that are hard to stop 
• Blood in the urine or stool 
• Pain and swelling in the joints due to internal bleeding 
• Infantile bleeding after birth or circumcision 
• Headaches and difficulties with vision 
http://www.innerbody.com/diseases-conditions/hemophilia  
 
 
Hemophilia (HL): 
clinical presentation 2 
 Frequency and sites of bleeding in patients with severe and moderate HL A 
http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2014;volume=140;issue=1;spage=19;epage=31;aulast=Kar  
 
 
Hemophilia (HL):  
clinical presentation 3 
• Bleeding may occur anywhere in the body 
• The most serious sites of bleeding are joints, muscles, digestive tract and 
brain 
• Muscle and joint haemorrhages (hemarthrosis) are indicative of 
hemophilia, while digestive tract and cerebral haemorrhages are also 
germane to other coagulation disorders 
• Though typically not life-threatening, joint bleeds are one of the most 
serious symptoms of HL 
• Repeated bleeds into a joint capsule can cause permanent joint damage 
and disfigurement resulting in chronic arthritis and disability 
• Joint damage is not a result of blood in the capsule but rather the healing 
process 
• When blood in the joint is broken down by enzymes in the body, the bone 
in that area is also degraded  
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL):  
clinical presentation 4 
Relationship Between Symptoms, Topic and Severity of HL 
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
 
 
 
 
Topic 
Severity of HL 
Severe Moderate Mild 
Cause of bleeding Spontaneous 
Minor trauma, not 
commonly 
spontaneous 
Major trauma, 
surgery 
Frequency of 
bleeding 
2 – 4/month 4 – 6/year Uncommon 
Pattern of bleeding 
Joint, soft tissue, 
bleeding after 
circumcision, 
neonatal 
intracranial 
hemorrhage, 
bleeding with 
surgical procedures 
Joint, soft tissue +/- 
bleeding after 
circumcision, +/- 
neonatal 
intracranial 
hemorrhage, 
bleeding with 
surgical procedures 
Joint, soft tissue, 
+/- bleeding after 
circumcision, 
bleeding with 
surgical procedures 
Hemophilia (HL): 
complications 1 
Complications may be both directly from the disease or from its treatment: 
• Deep internal bleeding, e.g. deep-muscle bleeding, leading to swelling, 
numbness or pain of a limb 
• Joint damage from hemarthrosis (hemophilic arthropathy), potentially with 
severe pain, disfigurement, and even destruction of the joint and development 
of debilitating arthritis 
• Transfusion transmitted infection from blood transfusions that are given as 
treatment 
• Adverse reactions to clotting factor treatment, including the development of an 
immune inhibitor which renders factor replacement less effective 
• Intracranial hemorrhage is a serious medical emergency caused by the buildup 
of pressure inside the skull, that can cause disorientation, nausea, loss of 
consciousness, brain damage, and death 
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
complications 2 
http://www.obizur.com/images/hemo-bleed.png  http://hubpages.com/health/Bleeding-Disorders-Due-To-Deficiency-Of-Coagulation-Factors-Hemophilia-A-Factor-VIII-deficiency#  
http://www.hemophiliabangalore.org/images/gall-2.jpg  https://i.ytimg.com/vi/hzb_RHk0-fI/hqdefault.jpg  http://pocketdentistry.com/25-congenital-bleeding-and-hypercoagulable-disorders/ 
 
HL bleedings 
Hemophilia (HL): 
diagnosis 1 
• Personal history of bleeding 
• Family history of bleeding and its inheritance 
pattern 
• Laboratory evaluation 
• Genetic testing to determine an individual's risk 
of attaining or passing on HL 
https://en.wikipedia.org/wiki/Hodgkin%27s_lymphoma  
 
 
Hemophilia (HL): 
diagnosis 2 
Laboratory Evaluation 
• In a patient with suspected HL, screening coagulation tests along with mixing 
studies are performed 
• The activated partial thromboplastin time (aPTT) assay evaluates the intrinsic 
pathway of coagulation and is quite often prolonged in patients with HL 
• If the aPTT is prolonged, a mixing study is performed to evaluate the correction 
of a patient’s aPTT with a pooled plasma from healthy donors 
• In patients with coagulation factor deficiencies, the aPTT is corrected in a 1:1 
mixing study 
• If a factor deficiency is suspected, then specific factor assays such as FVIII and 
FIX levels are performed to diagnose the type and severity of the deficiency  
• In patients with mild hemophilia, the aPTT assay may be normal 
• Once the diagnosis of HL is established, the screening of other at-risk family 
members, including females, should be performed to diagnose other affected 
individuals and determine the clotting factor level of carriers  
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
 
 
Hemophilia (HL): 
treatment 1  
• Treatment is comprehensive and focused on preserving both physical 
health and quality of life of individuals with the disorder 
• The primary goal of treatment is the prevention or cessation of bleeding 
episodes 
• Prompt treatment of acute bleeding episodes is essential to minimize 
long-term complications 
• Both nonpharmacologic and pharmacologic strategies are used in the 
treatment  
http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/hemophilia-etiology-complications-and-current-  
 
 
Hemophilia (HL): 
treatment 2  
Nonpharmacologic therapy consists of supportive care 
• Rest, ice, compression, and elevation (RICE) are important measures for 
treatment of joint or muscle bleeding episodes 
• Splints, crutches, or casts can be used to allow the affected joint or muscle 
to rest after a bleeding episode 
• Cold or ice compresses can help reduce associated inflammation and 
should be applied for 20 minutes every 4 to 6 hours 
• Once pain and swelling begin to resolve, physiotherapy can be initiated to 
maintain joint and muscle function  
• It is recommended that people affected with HL do specific exercises to 
strengthen the joints, particularly the elbows, knees, and ankles which 
increase flexibility, tone, and strength of muscles, increasing their ability to 
protect joints from damaging bleed  
 en.wikipedia.org/wiki/Haemophilia  formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/hemophilia-etiology-complications-and-current-  
 
 
Hemophilia (HL): 
treatment 3  
Pharmacologic strategies 
• Though there is no cure for HL, it can be controlled with regular infusions 
of the deficient clotting factor, i.e. factor VIII in HL A or factor IX in HL B 
• Factor replacement can be either isolated from human blood 
serum, recombinant, or a combination of the two 
• Some patients develop antibodies (inhibitors) against the replacement 
factors given to them, so the amount of the factor has to be increased or 
non-human replacement products must be given, such as porcine factor 
VIII 
• If a patient becomes refractory to replacement coagulation factor as a 
result of circulating inhibitors, this may be partially overcome with 
recombinant human factor VII   
en.wikipedia.org/wiki/Haemophilia formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/hemophilia-etiology-complications-and-current-  
 
 
Hemophilia (HL): 
treatment 4  
Treatment regimens 
• Prophylactic Infusion (Prophylaxis) as optimal therapy for patients with 
severe HL A or B involves regular administration of clotting factor 
concentrates, often 2 to 3 times per week, to increase the factor level to a 
moderate range (> 1%) to prevent spontaneous bleeding or bleeding after 
minor injury 
• Episodic Infusion (“On-Demand”) treatment is defined as utilization of 
clotting factor concentrates in response to an acute bleeding episode to 
stop bleeding after it has started 
• In general, individuals with mild and moderate HL, who tend to bleed less 
frequently, use episodic infusion of factor concentrates  
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
 
 
Hemophilia (HL): 
treatment 5  
New approaches (gene therapy) 
• On 10 December 2011, a team of British and American investigators 
reported the successful treatment of HL B using gene therapy 
• The investigators inserted the F9 gene into an adeno-associated virus-8 
vector, which has a propensity for the liver, where factor 9 is produced, 
and remains outside the chromosomes so as not to disrupt other genes 
• The transduced virus was infused intravenously 
• To prevent rejection, the people were primed with steroids to suppress 
their immune response 
• In October 2013, the Royal Free London National Health Society 
Foundation Trust in London reported that after treating six people with HL 
in early 2011 with the genetically modified adeno-associated virus, over 
two years later all were still producing blood plasma clotting factor 
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
treatment 6  
Contraindication  
• Anticoagulants such as heparin and warfarin are contraindicated for 
people with HL as these can aggravate clotting difficulties 
• Contraindicated are also those drugs which have "blood thinning" side 
effect (medicines which contain aspirin, ibuprofen, or naproxen sodium) 
• Contraindicated are activities with a high likelihood of trauma, such 
as motorcycling and skateboarding, American 
football, hockey, boxing, wrestling, rugby,  soccer, baseball, and basketball 
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
prognosis 
• People with severe HL who don't receive adequate, modern treatment 
have greatly shortened lifespans and often do not reach maturity 
• Prior to the 1960s when effective treatment became available, average life 
expectancy was only 11 years 
• By the 1980s the life span of the average haemophiliac receiving 
appropriate treatment was 50–60 years 
• Today with appropriate treatment, males with HL typically have a near 
normal quality of life with an average lifespan approximately 10 years 
shorter than an unaffected male 
https://en.wikipedia.org/wiki/Haemophilia  
 
 
Hemophilia (HL): 
clinical case 1a 
• NS is a recognized complication of immune tolerance induction (ITI) 
therapy, a treatment strategy used to treat inhibitors in patients with HL B 
receiving factor IX concentrate 
• There was presentation of  a 4-year-old boy with HL B and an inhibitor 
who underwent ITI, and developed NS 19 months into this therapy 
• A percutaneous renal biopsy was safely performed with factor IX (FIX) 
concentrate administration both preceding and following the procedure 
• The patient's inhibitor level had increased to 1.4-1.6 Bethesda Units just 
prior to the onset of proteinuria 
• Histology confirmed segmental membranous nephropathy (MGN)  
http://dgcases.docguide.com/successful-management-factor-ix-inhibitor-associated-nephrotic-syndrome-hemophilia-b-patient  
 
 Successful management of factor IX inhibitor-associated 
nephrotic syndrome (NS) in a hemophilia B patient 
Hemophilia (HL): 
clinical case 1b 
• The patient was continued on FIX concentrate as ITI and also received 4 
weekly doses of rituximab and ongoing immunosuppression with 
mycophenolate mofetil 
• This resulted in the complete resolution of his inhibitor and his NS 
• He continues with a modified ITI regimen and remains inhibitor-free 
without proteinuria >12 months post-biopsy 
• HL B patients undergoing ITI should be regularly screened for NS 
• At first detection of proteinuria, with proper precautions, a percutaneous 
kidney biopsy can be performed safely in patients with low levels of 
inhibitor  
http://dgcases.docguide.com/successful-management-factor-ix-inhibitor-associated-nephrotic-syndrome-hemophilia-b-patient  
 
 Successful management of factor IX inhibitor-associated 
nephrotic syndrome (NS) in a hemophilia B patient 
Hemophilia (HL): 
clinical case 2 
• An 11-year-old male with HL A and a known high-titer Factor VIII inhibitor 
was admitted with retroperitoneal hemorrhage 
• The patient was receiving infusions of recombinant activated Factor VII 
(rFVIIa) for a recent elbow hemorrhage when retroperitoneal bleeding 
commenced 
• Despite increased dosing of rFVIIa and a dose of activated prothrombin 
complex concentrate (aPCC), he continued to hemorrhage and required 
several blood transfusions 
• Factor XIII was administered 1 hour after rFVIIa and the patient 
demonstrated cessation of bleeding and normalization of clot strength 
• Factor XIII may act as an adjuvant in effective clot stabilization in patients 
with HL and inhibitory antibodies 
http://dgcases.docguide.com/treatment-refractory-hemorrhage-factor-xiii-patient-hemophilia-inhibitor  
 
 Treatment of refractory hemorrhage with Factor XIII in a 
patient with HL A with inhibitor 
Hemophilia (HL): 
clinical case 3a 
• HL is a congenital coagulation defect brought about by the deficiency or 
lack of coagulation factor IX 
• The prevalence of coronary artery disease and ACS is lower among 
hemophiliacs than in the normal population 
• Data regarding a treatment protocol for ACS and PCI in patients with HL 
limited 
• There was a report of a 41-year-old male patient with HL B who presented 
with a non-ST elevation myocardial infarction, and in whom PCI was 
performed following monitoring of factor IX levels 
• The patient had no cardiovascular risk factor except smoking 
http://dgcases.docguide.com/successful-percutaneous-coronary-intervention-acute-coronary-syndrome-patient-haemophilia-b  
 
 Successful percutaneous coronary intervention (PCI) for acute 
coronary syndrome (ACS) in a patient with HL B 
Hemophilia (HL): 
prophylaxis 
Patients are advised to 
• Stay up-to-date on vaccinations 
• Attend annual comprehensive clinic evaluations 
• Avoid situations and high-risk activities that may cause bleeding 
• Maintain good oral hygiene (to prevent extensive dental procedures) 
• Exercise regularly and maintain a healthy body weight 
• Identify and treat bleeding events promptly, as directed by the 
hematologist 
http://www.ihtc.org/medical-professionals/blood-disorders/bleeding-disorders/hemophilia-a-and-b/  
Hemophilia (HL): 
abbreviations  
• ACS        - acute coronary syndrome 
• aPCC    - activated prothrombin complex  
• aPTT     - activated partial thromboplastin time 
• ITI           - immune tolerance induction 
• HL         - Hemophilia 
• NS           - nephrotic syndrome 
• PCI         - percutaneous coronary intervention 
• pPTA     - plasma thromboplastin antecedent 
• rFVIIa    - recombinant activated Factor VII 
Hemophilia (HL): 
diagnostic and treatment guidelines 
• Guidelines for the Management of Hemophilia 
• WFH Treatment Guidelines - World Federation of Hemophilia 
• Consensus recommendations for the diagnosis and treatment of acquired 
hemophilia A 
• Diagnosis & Treatment Guidelines for Bleeding Management 
• Haemophilia - Diagnosis - Guidelines - Best Practice 
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Thrombocytopenic purpura (TP):  
definition 
Thrombocytopenic purpura is purpura associated with a reduction in 
circulating blood platelets which can result from a variety of causes 
 
Types 
• Immune TP (primary immune thrombocytopenia, primary immune 
TP or autoimmune TP), in most cases is immune-mediated and is defined 
as isolated low platelet count with normal bone marrow  
• Thrombotic TP (acquired - Moschcowitz syndrome, genetically inherited - 
Upshaw–Schulman syndrome), is a rare disorder of the blood-
coagulation system, arising from inhibition or dysfunction of 
the enzyme ADAMTS13, and causing extensive microscopic clots (thrombi) 
to form in the small blood vessels throughout the body 
 
 
 en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura en.wikipedia.org/wiki/Thrombocytopenic_purpura  
Thrombocytopenic purpura (TP):   
epidemiology  1 
• The incidence of Immune TP is estimated at 50–100 new cases per million 
people per year, with children accounting for half of that amount 
• At least 70% of childhood cases will end up in remission within six months, 
even without treatment 
• A third of the remaining chronic cases will usually remit during follow-up 
observation, and another third will end up with only mild thrombocytopenia 
(defined as a platelet count above 50,000) 
• Immune TP is usually chronic in adults and the probability of durable 
remission is 20–40% 
• The male to female ratio in the adult group varies from 1:1.2 to 1.7 
• The mortality rate due to chronic Immune TP varies but tends to be higher 
relative to the general population for any age range 
• No significant difference was noted in the rate of survival between males 
and females  
https://en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Pathogenesis  
Thrombocytopenic purpura (TP):   
epidemiology  2 
• The incidence of Thrombotic TP is about 4-5 cases per million people per 
year 
• Idiopathic Thrombotic TP occurs more often in women and people of African 
descent 
• Thrombotic TP secondary to autoimmune disorders such as systemic lupus 
erythematosus occurs more frequently in people of African descent  
• Untreated, Thrombotic TP has a mortality rate of as high as 90% 
• With plasma exchange, the mortality rate is reduced to 10-20% 
• Acute morbidities include ischemic events such as stroke, transient ischemic 
attacks, myocardial infarction and arrhythmia, bleeding, and azotemia 
• TTP during pregnancy may precipitate fetal loss 
• In general, survivors have no long-term sequelae, with the exception of 
residual neurologic deficits in a minority of patients 
• Relapses are not uncommon, occurring in 13-36% of patients 
https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause  http://emedicine.medscape.com/article/206598-overview#a6  
Thrombocytopenic purpura (TP):   
epidemiology  3 
Immune TP incidence rates according to age and sex. The horizontal bars 
correspond to incidence rates using a platelet count cut-off point of 50 × 109/L. 
 www.bloodjournal.org/content/94/3/909?sso-checked=true  
Thrombocytopenic purpura (TP):   
risk factors and etiology    
Immune TP  
• The acute form often follows an infection and has a spontaneous resolution 
within 2 months 
• The chronic form persists longer than 6 months with a specific cause being 
unknown 
• Immune TP can be triggered by drugs, or associated with infection, pregnancy, 
or immune disorders such as systemic lupus erythematosus, but about half of 
all cases are classified as "idiopathic," meaning the cause is unknown 
Thrombotic TP 
• Acquired forms arise from inhibition of the enzyme ADAMTS13, 
a metalloprotease responsible for cleaving large multimers of von Willebrand 
factor (vWF) into smaller units with increased platelet adhesion to areas 
of endothelial injury, particularly at arteriole-capillary junctions  
• Genetically inherited form arising from dysfunction of ADAMTS13 with 
tendency for increased coagulation exists 
 
 en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura  medicinenet.com/script/main/art.asp?articlekey=24151  
Thrombocytopenic purpura (TP): 
mechanisms 1   
Immune TP  
• In 60% of cases, antibodies 
against platelet membrane 
glycoproteins IIb-IIIa or Ib-IX can 
be detected, and are of 
the immunoglobulin G (IgG) type 
• The coating of platelets with IgG 
renders them susceptible 
to opsonization and phagocytosis 
by splenic macrophages, as well 
by Kupffer cells in the liver 
• The IgG autoantibodies are also 
thought to damage 
megakaryocytes    
 
Thrombotic TP 
• Thrombotic TP is characterized by 
clotting in small blood vessels of 
the body (thromboses), resulting 
in a low platelet count 
• In its full-blown form, the disease 
consists of the pentad of 
microangiopathic hemolytic 
anemia, thrombocytopenic 
purpura, neurologic 
abnormalities, fever, and renal 
disease 
• Reduced blood flow due to 
thrombosis and cellular injury 
results in end organ damage 
en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause  en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Pathogenesis  
emedicine.medscape.com/article/206598-overview  
Thrombocytopenic purpura (TP): 
mechanisms 2   
Mechanism of platelet destruction in Immune TP  
  
http://www.medscape.org/viewarticle/420904_6  
Thrombocytopenic purpura (TP): 
mechanisms 3   
Model of platelet autoantibody production in Immune TP   
  
http://4.bp.blogspot.com/_uiyskjNZYt8/TAevdJAWUSI/AAAAAAAABrU/cPJSHNFjl_g/s1600/Immune+thrombocytopenic+purpura.gif  
Thrombocytopenic purpura (TP): 
mechanisms 4   
Mechanisms of virus-induced thrombocytopenia  
http://www.frontiersin.org/files/Articles/124104/fimmu-05-00649-HTML/image_m/fimmu-05-00649-g001.jpg  
Thrombocytopenic purpura (TP): 
classification  1 
Immune TP  
• Primary  (hereditary, idiopathic acquired ) 
• Secondary (human immunodeficiency virus (HIV), hepatitis C, Helicobacter 
pylori, immunodeficiencies, Evans' syndrome, autoimmune (systemic lupus 
erythematosus (SLE), rheumatoid arthritis (RA)), lymphoproliferative disorders, 
adenocarcinoma, drug-induced) 
Thrombotic TP  
• Primary  (hereditary, idiopathic acquired ) 
• Secondary (HIV, pregnancy, bacterial endocarditis, autoimmune (SLE, RA), 
lymphoproliferative disorders, adenocarcinoma, drug induced (ticlopidine, oral 
contraceptives, iodine, sulfonamides) 
http://shp.missouri.edu/vhct/case2300/types_ttp.htm  bestpractice.bmj.com/best-practice/monograph/138/basics/classification.html  
Thrombocytopenic purpura (TP): 
clinical presentation 1 
 
Immune TP  
 
• Bruising  
• Petechiae  
• Purpura 
• Prolonged bleeding from cuts 
• Spontaneous bleeding from 
nose 
• Bleeding gums, especially after 
dental work 
• Blood in urine or stools 
• Unusually heavy menstrual 
flow 
• Fatigue 
 
Thrombotic TP  
 
• Bruising 
• Petechiae 
• Purpura  
• Mucosal bleeding 
• Microangiopathic hemolytic anemia  
• Neurologic symptoms 
(hallucinations, bizarre 
behavior, delirium, stroke, 
hemiplegia, paresthesias, visual 
disturbance,  aphasia, headaches) 
• Kidney failure 
• Fever   
 
https://www.merckmanuals.com/professional/hematology-and-oncology/thrombocytopenia-and-platelet-dysfunction/immune-thrombocytopenia-(itp) 
http://www.mayoclinic.org/diseases-conditions/idiopathic-thrombocytopenic-purpura/basics/symptoms/con-20034239 http://emedicine.medscape.com/article/206598-overview   
Thrombocytopenic purpura (TP):   
clinical presentation 2 
Petechiae (red/purple dots) and purpura (bruises) in the skin 
http://www.skinerrors.com/wp-content/uploads/Idiopathic-thrombocytopenic-purpura.jpg  https://my.clevelandclinic.org/health/diseases_conditions/hic-immune-thrombocytopenia  
https://upload.wikimedia.org/wikipedia/commons/0/02/Oral_petechiae.JPG  http://www.primehealthchannel.com/idiopathic-thrombocytopenic-purpura.html  http://healthool.com/purpura/   
 
 
Thrombocytopenic purpura (TP): 
diagnosis   
 
Immune TP  
 • The diagnosis is a process of 
exclusion 
• It has to be determined that there 
are no blood abnormalities other 
than a low platelet count, and no 
physical signs other than bleeding 
• Secondary causes should be 
excluded  
• Bone marrow examination is not 
required to make the diagnosis 
but is done if blood counts or 
blood smear reveals abnormalities 
in addition to thrombocytopenia, 
when clinical features are not 
typical, or if patients fail to 
respond to standard therapies 
 
Thrombotic TP  
 • Measuring ADAMTS13 activity level 
• Laboratory studies 
• Complete blood count (CBC) 
• Total white blood cell count is normal or 
slightly elevated 
• Hemoglobin concentration is moderately 
depressed at 8-9 g/dL 
• Platelet count generally ranges from 20,000-
50,000/μL 
• coagulation studies 
• Blood urea nitrogen (BUN) creatinine,  
• serum bilirubin and lactate dehydrogenase as 
indirect measures of the degree of hemolysis 
• Imaging studies and biopsies are not required for 
diagnosis 
emedicine.medscape.com/article/206598-overview en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Diagnosis  
merckmanuals.com/professional/hematology-and-oncology/thrombocytopenia-and-platelet-dysfunction/immune-thrombocytopenia-(itp)   
Thrombocytopenic purpura (TP): 
treatment   
Immune TP  
 • There is usually no need to treat based on platelet counts 
• Current guidelines recommend treatment only in cases of 
significant bleeding 
• Initial treatment usually consists of corticosteroids, the dose 
and mode of administration is determined by platelet count 
and whether there is active bleeding 
•  In chronic refractory cases,  immunosuppresants 
( mycophenolate mofetil and azathioprine) 
and chemotherapy (vincristine) agent may be attempted 
• Anti-RhD therapy for patients with certain blood types 
• Infusions of high-dose gamma globulin 
• Thrombopoietin receptor agonists (romiplostim, 
eltrombopag) that stimulate the bone marrow to make more 
platelets 
• Platelet transfusion is recommended in an emergency  
 
Thrombotic TP  
 • The therapy of 
choice is plasma 
exchange with fresh 
frozen plasma 
• Another option, is 
intravenous 
administration of  
octaplas, a sterile, 
frozen solution of 
pooled human 
plasma from several 
donors as 
alternative to single-
donor plasma 
• Corticosteroids may 
also be used in 
refractory patients 
https://en.wikipedia.org/wiki/Idiopathic_thrombocytopenic_purpura#Treatment https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause 
http://emedicine.medscape.com/article/206598-overview   
Thrombocytopenic purpura (TP): 
prognosis   
 
Immune TP  
 
• With treatment, the chance of 
remission (a symptom-free 
period) is good 
• In rare cases, disease may 
become a long-term condition in 
adults and reappear, even after a 
symptom-free period 
 
Thrombotic TP  
 
• The mortality rate is around 
95% for untreated cases, but 
the prognosis is reasonably 
favorable (80–90% survival) 
for patients diagnosed and 
treated early 
with plasmapheresis 
https://www.nlm.nih.gov/medlineplus/ency/article/000535.htm https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura#Unknown_cause   
Thrombocytopenic purpura (TP): 
prophylaxis 
• There is no known way to prevent Immune TP and Thrombotic 
TP  
 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0023094/  https://www.nlm.nih.gov/medlineplus/ency/article/000535.htm  
Thrombocytopenic purpura (TP):   
clinical case 1a 
• Romiplostim, a thrombopoietin mimetic, is a novel therapeutic option for 
patients with chronic immune TP 
• A 28-year-old primigravid woman with chronic immune TP initiated a 
planned pregnancy on romiplostim 
• The second and third trimesters were marked by a cyclic pattern of 
thrombocytopenia requiring supplemental corticosteroids or intravenous 
immunoglobulin and resultant thrombocytosis 
• Increased romiplostim doses and daily corticosteroids stabilized the 
platelet count before induction of labor at 33 weeks of gestation  
http://dgcases.docguide.com/use-thrombopoietin-mimetic-chronic-immune-thrombocytopenic-purpura-pregnancy  
 
 Use of a thrombopoietin mimetic for chronic immune 
thrombocytopenic purpura (TP) in pregnancy 
Thrombocytopenic purpura (TP):   
clinical case 1b 
• The newborn manifested intraventricular hemorrhage at birth, although 
no developmental delay was present on follow-up at 10 months of age 
• The decreased efficacy of romiplostim monotherapy is attributed to 
increased target-mediated drug disposition and the physiologic changes of 
pregnancy 
• Safety concerns still exist for the developmental effects of romiplostim on 
the fetus 
http://dgcases.docguide.com/use-thrombopoietin-mimetic-chronic-immune-thrombocytopenic-purpura-pregnancy  
 
 Use of a thrombopoietin mimetic for chronic immune 
thrombocytopenic purpura (TP) in pregnancy 
Thrombocytopenic purpura (TP):   
clinical case 2 
• A 49-year-old woman who had idiopathic TP was admitted to our hospital 
with severe chest pain 
• Electrocardiography revealed inferolateral myocardial infarction 
• The patient underwent immediate coronary angiography, which revealed 
thrombi in the left coronary system 
• Percutaneous intervention was not indicated, because the thrombi had 
occluded the distal segments of multiple coronary arteries 
• Administration of tirofiban satisfactorily dissolved the thrombi 
http://dgcases.docguide.com/use-thrombopoietin-mimetic-chronic-immune-thrombocytopenic-purpura-pregnancy  
 
 Multivessel coronary thrombosis in a patient with idiopathic TP 
Thrombocytopenic purpura (TP):   
clinical case 3 
• The hereditary or acquired deficiency of ADAMTS-13 activity leads to an 
excess of high molecular weight von Willebrand factor multimers in plasma, 
leading to platelet aggregation and diffuse intravascular thrombus 
formation, resulting in Thrombotic TP 
• There was a report of a 36 year old male with a long history of Thrombotic 
TP associated with 33 relapses 
• As a result of early transfusions, the patient acquired Hepatitis C 
• This time, the patient presented with a Thrombotic TP relapse after a 10 
year remission, following PEG-interferon-Alpha (IFA) therapy for Hepatitis C 
• Since IFA has been reported to activate autoimmune reactions, it may have 
augmented production of ADAMTS-13 antibody 
http://dgcases.docguide.com/thrombotic-thrombocytopenic-purpura-unusual-33-recurrences-case-report  
 
 Thrombotic TP with unusual 33 recurrences: a case report 
Thrombocytopenic purpura (TP): 
abbreviations  
• CBC  - complete blood count 
• IFA   - interferon-alpha   
• HIV   - human immunodeficiency virus  
• RA    - rheumatoid arthritis 
• SLE   - systemic lupus erythematosus  
• TP    - thrombocytopenic purpura 
• vWF - von Willebrand factor 
Thrombocytopenic purpura (TP): 
diagnostic and treatment guidelines 
• Diagnosis and treatment of idiopathic thrombocytopenic 
purpura: recommendations of the American Society of 
Hematology. The American Society of Hematology ITP Practice 
Guideline Panel. 
• Management of Immune Thrombocytopenic Purpura: An 
Update 
• Immune Thrombocytopenic Purpura 
• Guidelines on the diagnosis and management of thrombotic 
thrombocytopenic purpura and other thrombotic 
microangiopathies 
